Lumosa Therapeutics Inc. (6535.TWO), a new drug research and development company, focused on developing novel treatments for neurological and inflammatory disorders, today announced that the Company will be presenting its LT3001 study at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9~11, 2022. For information about the event, visit: https://professional.heart.org/en/meetings/international-stroke-conference.

Presentation title: Combining Lysis with Neuroprotection in One Molecule (LT3001)
Presentation time: Wednesday, February 9th, 2022, 2~3PM
Session title: Novel Approaches to Attack the Clot: Beyond Tissue Plasminogen Activators
Session number: 085